Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks
M Galluzzo, L Marcelli, L Vellucci… - Expert Opinion on …, 2023 - Taylor & Francis
Background Real-world data are useful to guide the management of psoriasis. Here, we
present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic …
present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic …
[HTML][HTML] Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
SE Thomas, L Barenbrug, G Hannink, MMB Seyger… - Drugs, 2024 - Springer
Abstract Background and Objective The most recently approved biologics for moderate-to-
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …
severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently …
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III …
CT Ritchlin, PS Helliwell, WH Boehncke, ER Soriano… - RMD open, 2021 - rmdopen.bmj.com
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal
antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) …
antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) …
Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
M Megna, G Fabbrocini, E Cinelli… - Journal of …, 2022 - Taylor & Francis
Objectives We aimed to evaluate the effectiveness, safety and tolerability of guselkumab in a
real-life setting. Methods A prospective, observational, single-center, real-life study including …
real-life setting. Methods A prospective, observational, single-center, real-life study including …
Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: a retrospective, observational, multicentre study by the …
E Del Alcázar, A López‐Ferrer… - Dermatologic …, 2022 - Wiley Online Library
Data on the effectiveness and safety of a drug in real‐world clinical practice complement the
evidence from clinical trials, which are carried out in a different setting. Little has been …
evidence from clinical trials, which are carried out in a different setting. Little has been …
[PDF][PDF] Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study
AC Fougerousse, PD Ghislain, Z Reguiai… - J Eur Acad Dermatol …, 2020 - dial.uclouvain.be
A retrospective, real-life multicenter study conducted in France and Belgium evaluated
guselkumab tolerance and effectiveness at Month 4 (M4) in the treatment of cutaneous …
guselkumab tolerance and effectiveness at Month 4 (M4) in the treatment of cutaneous …
[HTML][HTML] Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data
A Ruggiero, M Megna, G Fabbrocini… - Immunologic …, 2023 - Springer
Nowadays, the biological equipment available for the treatment of moderate-to-severe
psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the …
psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the …
Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective …
JFB Schwensen, VW Nielsen… - Journal of the …, 2021 - search.ebscohost.com
Biologic treatment has revolutionized the management of psoriasis (PsO) but time to
discontinuation (drug survival) for biologic therapy is less than ideal and varies between the …
discontinuation (drug survival) for biologic therapy is less than ideal and varies between the …
[PDF][PDF] Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients.
G Malara, C Trifirò, A Bartolotta, C Giofré… - European Review for …, 2021 - europeanreview.org
OBJECTIVE: Guselkumab is a fully human monoclonal IgG1 antibody which, by selectively
binding to the p19 subunit of IL-23, prevents it from binding to the IL-23 receptor on the cell …
binding to the p19 subunit of IL-23, prevents it from binding to the IL-23 receptor on the cell …
Ustekinumab to guselkumab transitions: a series of 54 patients emulating the navigate trial in real life
S Berenguer‐Ruiz, R Rivera, P Herranz… - Dermatologic …, 2022 - Wiley Online Library
NAVIGATE clinical trial demonstrated a higher rate of Psoriasis Assesment Severity Index
(PASI) 90 response in patients treated with guselkumab when compared to ustekinumab …
(PASI) 90 response in patients treated with guselkumab when compared to ustekinumab …